Immunization Against Seasonal Flu and Sars-Cov-2 Virus: A Timeless Epidemic Study in Primary Health Care

Anastasia Galanopoulou, Dimitrios Gougourelas, Athina Maria Koufadaki, Eleftheria Lelekaki

Keywords: immunization, influenza, SARS-COV2 vaccination

Introduction:
Purpose: To record the demographic characteristics of the population vaccinated against seasonal flu and SARS-COV-2 and the outcome of their health in the last year, compared to the previous two years.

Method:
Material / Method: 571 adults participated, with a mean age of 68.8 ± 14.1 years (♂49% / ♀51%), who came to Health Center of Goura last year for influenza vaccination. Their somatometric and demographic data as well as the individual history of disease and immunization of previous years were recorded. Six months later, the same patients were called to answer questions about their health.

Results:
Results: Of those vaccinated against influenza, 6.7% became ill due to a respiratory infection. Of these, 60.5% received antibiotics, 68.4% inhaled medicines, while 7.8% were hospitalized. By comparison, in 2020, 14.7% of the same population became ill, 53.6% received antibiotics, 50% inhaled medicines and 21.4% were hospitalized. Of the participants, only 2.4% had not been vaccinated against influenza in 2020 and 29% in 2019. 48% had been immunized against pneumococcus. It is noteworthy that 2.5% of the total population was vaccinated with the conjugated polysaccharide pneumococcal vaccine (13-potency) for a second time. 6% were vaccinated against shingles and 91.1% against SARS-COV-2 virus, while the majority of vaccination side effects were mild. 9.3% developed COVID-19 before vaccination and 8.1% after it.

Conclusions:
Conclusions: Influenza disease has decreased rapidly in the last two years, a fact that is mainly attributed to the observance of the applied protection measures due to the pandemic. Factors such as age, smoking, comorbidities and social components were not statistically significantly associated with the disease. The rate of vaccination against SARS-COV-2 virus was high, while the serious side effects of the vaccine as well as disease rates recorded were low.

EQuiP Twitter Feed
EQuiP Facebook Feed